More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

The two-drug regimen dolutegravir/lamivudine is as effective as the three-drug regimen dolutegravir plus tenofovir ...

Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by starting HIV medication immediately ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

Brian Zanoni, MD, MPH, discusses forecasts that suggest declining global HIV rates but persistent gaps in care and funding.

Protecting public health abroad benefits Americans. In a globalized world, diseases and their social and economic impacts do ...

In the absence of a vaccine, injectable antibodies are currently being tested as a way to prevent HIV infection ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

A Prescription Drug User Fee Act target date of April 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir ...